Sacubitril/valsartan fails to prevent doxorubicin-induced cognitive impairment and hippocampal oxidative, inflammatory, and apoptotic alterations in rats

Combining VS with DOX did not significantly enhance spatial learning and working memory compared with DOX alone, nor did it mitigate neuroinjury. These findings suggest that VS is not a viable therapeutic agent for alleviating DOX-induced neurotoxicity and cognitive dysfunction. This research offers novel insight for the field of pharmacological discovery by demonstrating that the neuroprotective potential of neprilysin inhibition (a key mechanism of VS) differs significantly from its cardioprotective actions. Our findings provide a foundational basis for the design of future neuroprotective therapies and for further research.